Drug intelligence / Profile preview

China Pharma Univ. CDK9 compound 32k

Development stage: Preclinical
Lead developer: China Pharmaceutical University

Overview

China Pharma Univ. CDK9 compound 32k: sourced facts only. name: "Compound 32k was identified as a selective CDK9 inhibitor with short pharmacokinetic and physicochemical properties suitable for intravenous administration." [PMID:35605362]; target: "Compound 32k was identified as a selective CDK9 inhibitor with short pharmacokinetic and physicochemical properties suitable for intravenous administration." [PMID:35605362]; developer: "School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, PR China." [PMID:35605362]; stage: "Correspondingly, significant in vivo antitumor efficacy was observed in xenograft models derived from multiple hematological tumors with intermittent 32k dosing." [PMID:35605362]

Targets

CDK9 (Cyclin-dependent kinase 9)

Beyond the preview

Go deeper on China Pharma Univ. CDK9 compound 32k.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China Pharma Univ. CDK9 compound 32k.